Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 198,328,720
  • Shares Outstanding, K 6,815,420
  • Annual Sales, $ 53,441 M
  • Annual Income, $ 9,723 M
  • 36-Month Beta 0.61
  • Price/Sales 3.97
  • Price/Cash Flow 16.06
  • Price/Book 7.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/01/17
  • Annual Dividend & Yield 0.85 (2.93%)
  • Most Recent Dividend 0.84 on 03/15/17
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.4800 +2.18%
on 11/09/17
31.2200 -6.79%
on 10/18/17
-2.3500 (-7.47%)
since 10/17/17
3-Month
28.4800 +2.18%
on 11/09/17
32.3100 -9.94%
on 09/25/17
-2.4400 (-7.74%)
since 08/17/17
52-Week
25.2500 +15.25%
on 12/08/16
36.8200 -20.97%
on 04/28/17
+0.0930 (+0.32%)
since 11/17/16

Most Recent Stories

More News
Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

NVS : 83.98 (+1.16%)
RHHBY : 29.1000 (+0.71%)
PFE : 35.37 (-0.53%)
BMY : 61.32 (-0.89%)
Cancer Space Update: Label Expansion for Three Major Drugs

This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

AVEO : 3.11 (+1.63%)
CELG : 104.10 (+0.73%)
AZN : 33.46 (-0.18%)
BLUE : 163.20 (+1.90%)
MRK : 55.20 (+0.05%)
RHHBY : 29.1000 (+0.71%)
PFE : 35.37 (-0.53%)
Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval

Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with...

NVO : 50.91 (+0.81%)
SHPG : 147.37 (+1.89%)
ABBV : 93.61 (-0.91%)
RHHBY : 29.1000 (+0.71%)
ADDING MULTIMEDIA FDA Approves Genentech's HEMLIBRA (emicizumab-kxwh) for Hemophilia A with Inhibitors

--- HEMLIBRA substantially reduced bleeds in adults and children -

RHHBY : 29.1000 (+0.71%)
FDA Approves Genentech's Gazyva for Previously Untreated Advanced Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Gazyva(R) (obinutuzumab) in combination with...

RHHBY : 29.1000 (+0.71%)
FDA Approves Genentech's HEMLIBRA (emicizumab-kxwh) for Hemophilia A with Inhibitors

--- HEMLIBRA substantially reduced bleeds in adults and children -

RHHBY : 29.1000 (+0.71%)
Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?

Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.

ALNY : 127.51 (+0.89%)
NVS : 83.98 (+1.16%)
RHHBY : 29.1000 (+0.71%)
SNY : 44.54 (-0.25%)
Roche launches DISCOVERY Teal HRP chromogen detection kit to advance tissue-based cancer research

TUCSON, Ariz. , Nov. 16, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the DISCOVERY Teal HRP kit 1 , the newest addition to the comprehensive collection...

ROG : 158.40 (+0.06%)
RHHBY : 29.1000 (+0.71%)
Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

Roche's (RHHBY) diagnostic portfolio gets a further boost with FDA's clearance for Ventana tests.

CORT : 18.39 (-3.46%)
SCMP : 10.55 (+1.93%)
NVS : 83.98 (+1.16%)
RHHBY : 29.1000 (+0.71%)
Shire Gets Positive CHMP Opinion for Hemophilia A Drug

Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

CORT : 18.39 (-3.46%)
LGND : 140.31 (-0.99%)
SHPG : 147.37 (+1.89%)
RHHBY : 29.1000 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Key Turning Points

2nd Resistance Point 29.2267
1st Resistance Point 29.1633
Last Price 29.1000
1st Support Level 28.9733
2nd Support Level 28.8467

See More

52-Week High 36.8200
Fibonacci 61.8% 32.4003
Fibonacci 50% 31.0350
Fibonacci 38.2% 29.6697
Last Price 29.1000
52-Week Low 25.2500

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart